Thetis Pharmaceuticals Awarded Key Patent on HEALER Technology

Thetis Pharmaceuticals LLC, announced today that the USPTO has granted patent US 9,242,008 providing composition of matter protection for two Thetis development candidates, TP-252 for familial adenomatous polyposis and TP-452 for dyslipidemia. The allowed claims include pharmaceutical compositions that are mineral amino-acid based derivatives of fatty acids. National filings outside of the United States are underway.
Frank Sciavolino, Ph.D., co-founder, president and chief scientific officer of Thetis said:

This patent is a cornerstone of our strategy to develop innovative prescription drug products based on small molecule derivatives of fatty acids. The patent further extends our HEALER technology platform, which enables development of eicosanoid-based agents in multiple therapeutic areas. Our agents deliver high plasma levels of fatty acids which are metabolically converted into lipid mediators with potent pharmacology. The industry has been seeking to harness this biology for decades but lipid mediators have proven to be unsuitable for drug development. Our HEALER technology overcomes this hurdle.

Click here to view the press release.